Innovent Partners with Synaffix to Create ADC Candidate from Antibody
publication date: Jun 29, 2021
Suzhou Innovent Bio signed a non-exclusive, target-specific license to use antibody-drug conjugate technology developed by Amsterdam's Synaffix. Synaffix will employ its programs to create an ADC candidate based on one of Innovent's antibodies. Synaffix will manufacture components that are specifically related to its proprietary technologies, but Innovent will be responsible for the rest of the product's development. Synaffix is eligible to receive upfront, potential milestone and royalty payments, though details were not disclosed. More details....
Stock Symbol: (HK: 01801)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.